Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

Top-Line Psoriasis Efficacy Bested Placebo; Safety Similar To Phase II

 
• By Mandy Jackson
  
Dart arrow hitting in the target center of dartboard using as background Target business, achieve and victory,success concept.
Oral TYK2 inhibitor deucravacitinib (BMS-986165) met both primary endpoints in its first Phase III psoriasis study
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

More from Therapeutic Category